Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update
Open accessThe DOI matches its Crossref record.
Abstract
Purpose: To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epoetin. The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents. Method: An Update Committee (“Committee”) reviewed and analyzed data published since 2002 through July 2007. MEDLINE and the Cochrane Collaboration Library databases were searched. Recommendations: For patients with chemotherapy-associated anemia, the Committee continues to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb) approaches, or falls below, 10 g/dL, to increase Hb and decrease transfusions. ESA treatment continues to be recommended for patients with low-risk myelodysplasia for similar reasons. There is no evidence showing increased survival as a result of ESA treatment. Conclusive evidence is lacking that, absent clinical circumstances necessitating earlier treatment, initiating ESAs at Hb levels greater than 10 g/dL either spares more patients from transfusion or substantially improves their quality of life. Starting doses and dose modifications based on response or lack thereof should follow the package insert. Continuing ESAs beyond 6 to 8 weeks in the absence of response, assuming appropriate dose increase has been attempted in nonresponders as per US Food and Drug Administration–approved label, does not seem to be beneficial, and ESA therapy should be discontinued. The Committee recommends monitoring iron stores and supplementing iron intake for ESA-treated patients. ESAs should be used cautiously with chemotherapy, or in clinical states, associated with elevated risk for thromoembolic complications. The Committee also cautions against ESA use for patients with cancer who are not receiving chemotherapy, since recent trials report increased thromboembolic risks and decreased survival under these circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care*
Napolitano, L. M., Kurek, S., Luchette, F. A., Corwin, H. L., Barie, P. S., Tisherman, S. A., Hebert, P. C., Anderson, G. L., Bard, M. R., Bromberg, W., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b39f1b · Cited by 551
Goodnough, L. T., Maniatis, A., Earnshaw, P., Benoni, G., Beris, P., Bisbe, E., Fergusson, D. A., Gombotz, H., Habler, O., Monk, T. G., et al. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aeq361 · Cited by 543
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Jädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4906 · Cited by 300
Linking anemia to inflammation and cancer: The crucial role of TNFα
Buck, I., Morceau, F., Grigorakaki, C., Dicato, M., & Diederich, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.018 · Cited by 66
“However, the confl icting effects of ESAs were recently described in distinct studies [70-72].”
Metadata
- Authors
- Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Rarick, M. U., Regan, D. H., & Lichtin, A. E.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-01-01
- Volume
- 111
- Issue
- 1
- Pages
- 25-41
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2060577710
- Cited by
- 151
- References
- 0
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. https://app.cochat.ai/papers/10.1182/blood-2007-08-109488
- The paper
- Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Rarick, M. U., Regan, D. H., & Lichtin, A. E. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. https://doi.org/10.1182/blood-2007-08-109488
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.